Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Yao C, Kong J, Xu F, Wang S, Wu S, Sun W, et al
Incidence of diabetic retinopathy did not differ between the orforglipron and placebo groups, and no hepatic safety signals were observed in the trial
Clinical trial data used doses ranging from 1 mg to 12 mg/week, with most research subjects in community settings staying in the 2 mg to 4 mg/week range for a balance of efficacy and tolerability
The decision was not related to data from any clinical program and there have been no observed or reported safety concerns, Equillium stated
US$ 29.34
US$ 23.40
US$ 28.94
US$ 25.93
US$ 25.60
